Display options
Share it on

Front Pharmacol. 2018 Feb 12;9:98. doi: 10.3389/fphar.2018.00098. eCollection 2018.

Usage of Mitogen-Activated Protein Kinase Small Molecule Inhibitors: More Than Just Inhibition!.

Frontiers in pharmacology

Steffen K Meurer, Ralf Weiskirchen

Affiliations

  1. Institute of Molecular Pathobiochemistry, Experimental Gene, and Clinical Chemistry, RWTH Aachen University, Aachen, Germany.

PMID: 29483873 PMCID: PMC5816342 DOI: 10.3389/fphar.2018.00098

Abstract

We have identified a phenomenon occurring in the usage of proposed "specific" Mitogen-activated protein kinase (MAPK) inhibitors. We found that especially inhibitors of p38 potentiate the activation of other MAPKs in various cell types. This finding will have tremendous impact on the interpretation of all former studies using MAPK inhibitors.

Keywords: PD98059; PDGF-BB; SB203580; SP600125; UO126; inhibitors; mitogen-activated protein kinases; signal transduction

References

  1. Proc Natl Acad Sci U S A. 2001 Nov 20;98 (24):13681-6 - PubMed
  2. Biochem J. 2000 Oct 1;351(Pt 1):95-105 - PubMed
  3. FASEB J. 2008 Apr;22(4):954-65 - PubMed
  4. PLoS One. 2013;8(2):e56116 - PubMed
  5. Cell Signal. 2011 Apr;23 (4):683-99 - PubMed
  6. Br J Pharmacol. 2000 Sep;131(1):99-107 - PubMed
  7. Biochim Biophys Acta. 2016 Nov;1863(11):2604-2612 - PubMed
  8. Xenobiotica. 2002 Mar;32(3):221-33 - PubMed
  9. J Biol Chem. 2003 Jul 18;278(29):26715-21 - PubMed
  10. Nature. 1994 Dec 22-29;372(6508):739-46 - PubMed
  11. Antioxid Redox Signal. 2014 May 10;20(14):2251-73 - PubMed
  12. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7686-9 - PubMed
  13. Biochem J. 2003 Apr 1;371(Pt 1):199-204 - PubMed
  14. J Biol Chem. 1998 Jul 17;273(29):18623-32 - PubMed
  15. Cytokine Growth Factor Rev. 2016 Apr;28:53-61 - PubMed

Publication Types